Login
$PMVP
$1.15 -$0.04 (3.28%) After hours

Company Executives

Officer Age In this role 2025 pay Source
David H. Mack, Ph.D.
President, Chief Executive Officer and Director
64 Not stated $1,665,191
Michael Carulli
Chief Financial Officer
52 Since 2024
2 years
Not reported
Robert Ticktin
General Counsel and Chief Operating Officer
64 Since 2024
2 years
$861,206
Deepika Jalota, Pharm.D.
Chief Development Officer
50 Since 2023
3 years
Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Apr 22, 2026 · updated by the 8-K of Oct 5, 2026

Directors
6
serving now
Independent
5 of 5
stated in the proxy; 1 not stated
Director Independent Committees Source
Stelzer
Independent
audit · Chair compensation
Flowers
Independent
audit
Gallagher
Independent
nominating and corporate governance
Baum
Independent
compensation nominating and corporate governance · Chair
Matthew Eckler Joined Oct 1, 2026
- -
Heyman Leaving at the meeting
Independent
audit compensation · Chair nominating and corporate governance

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.

4 disclosed in the proxy filed Apr 22, 2026
Arnold Levine, Ph.D.
one of our co-founders and a member of our board of directors
$100,000
annual

Consulting and advisory services arrangement, with an annual cash payment to Dr. Levine; he also serves on the SAB.

Richard Heyman, Ph.D.
chairperson of our board of directors
Amount not stated

Service on the Scientific Advisory Board; Dr. Heyman waived his rights to SAB compensation effective September 2021.

Charles M. Baum, M.D., Ph.D.
a member of our board of directors
$100,000
February 2024 to January 2026

Prior consulting agreement for senior clinical advisory services, including chairing the CAB; terminated January 2026.

Charles M. Baum, M.D., Ph.D.
$20,000
annual, effective January 2026

Baum CAB Agreement for continued service as chairperson of the CAB, with an annual cash payment.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support